Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Corrigendum to "Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens" [Radiother. Oncol. 137 (2019) 24-31].
Meneceur S, Löck S, Gudziol V, Hering S, Bütof R, Rehm M, Baumann M, Krause M, von Neubeck C. Meneceur S, et al. Among authors: gudziol v. Radiother Oncol. 2023 Jun;183:109619. doi: 10.1016/j.radonc.2023.109619. Epub 2023 Mar 29. Radiother Oncol. 2023. PMID: 37001220 No abstract available.
FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy.
Zschaeck S, Löck S, Leger S, Haase R, Bandurska-Luque A, Appold S, Kotzerke J, Zips D, Richter C, Gudziol V, Schreiber A, Zöphel K, Baumann M, Krause M. Zschaeck S, et al. Among authors: gudziol v. Radiother Oncol. 2017 Mar;122(3):437-444. doi: 10.1016/j.radonc.2017.01.019. Epub 2017 Feb 17. Radiother Oncol. 2017. PMID: 28222892
HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Linge A, Lohaus F, Löck S, Nowak A, Gudziol V, Valentini C, von Neubeck C, Jütz M, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Krause M, Baumann M; DKTK-ROG. Linge A, et al. Among authors: gudziol v. Radiother Oncol. 2016 Dec;121(3):364-373. doi: 10.1016/j.radonc.2016.11.008. Epub 2016 Nov 29. Radiother Oncol. 2016. PMID: 27913065
Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
Linge A, Schötz U, Löck S, Lohaus F, von Neubeck C, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Lauber K, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Krause M, Belka C, Baumann M; DKTK-ROG. Linge A, et al. Among authors: gudziol v. Radiother Oncol. 2018 Apr;127(1):27-35. doi: 10.1016/j.radonc.2017.12.007. Epub 2017 Dec 30. Radiother Oncol. 2018. PMID: 29295747
Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S, Linge A, Seidlitz A, Bandurska-Luque A, Nowak A, Gudziol V, Buchholz F, Aust DE, Baretton GB, Zöphel K, Steinbach J, Kotzerke J, Overgaard J, Zips D, Krause M, Baumann M, Troost EGC. Löck S, et al. Among authors: gudziol v. Radiother Oncol. 2019 Jun;135:43-50. doi: 10.1016/j.radonc.2019.02.020. Epub 2019 Mar 9. Radiother Oncol. 2019. PMID: 31015169
Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy.
Patil S, Tawk B, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Baretton GB, Baumann M, Krause M, Löck S, Linge A; DKTK-ROG. Patil S, et al. Among authors: gudziol v. Radiother Oncol. 2022 Feb;167:300-307. doi: 10.1016/j.radonc.2021.12.049. Epub 2022 Jan 6. Radiother Oncol. 2022. PMID: 34999136
Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
Löck S, Linge A, Lohaus F, Ebert N, Gudziol V, Nowak A, Tinhofer I, Kalinauskaite G, Guberina M, Stuschke M, Balermpas P, von der Grün J, Grosu AL, Debus J, Ganswindt U, Belka C, Peeken JC, Combs SE, De-Colle C, Zips D, Baretton GB, Krause M, Baumann M; DKTK-ROG. Löck S, et al. Among authors: gudziol v. Radiother Oncol. 2022 Apr;169:8-14. doi: 10.1016/j.radonc.2022.02.009. Epub 2022 Feb 16. Radiother Oncol. 2022. PMID: 35182686
Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.
Patil S, Linge A, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Baretton GB, Baumann M, Krause M, Löck S; DKTK-ROG. Patil S, et al. Among authors: gudziol v. Radiother Oncol. 2022 Jun;171:91-100. doi: 10.1016/j.radonc.2022.04.006. Epub 2022 Apr 13. Radiother Oncol. 2022. PMID: 35429503
Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy.
Schmidt S, Linge A, Zwanenburg A, Leger S, Lohaus F, Krenn C, Appold S, Gudziol V, Nowak A, von Neubeck C, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S; DKTK-ROG. Schmidt S, et al. Among authors: gudziol v. Clin Cancer Res. 2018 Mar 15;24(6):1364-1374. doi: 10.1158/1078-0432.CCR-17-2345. Epub 2018 Jan 3. Clin Cancer Res. 2018. PMID: 29298797
68 results